Stay updated on Expanded Access of Lifileucel in Melanoma: Clinical Trial
Sign up to get notified when there's something new on the Expanded Access of Lifileucel in Melanoma: Clinical Trial page.

Latest updates to the Expanded Access of Lifileucel in Melanoma: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed information about the Expanded Access Program for AMTAGVI and its eligibility criteria, while introducing references to unresectable melanoma and a new version revision.SummaryDifference18%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe webpage has added several new hospital locations across various states, including California, Colorado, Connecticut, Illinois, and Iowa, while also updating the available date from February 2025 to March 2025.SummaryDifference4%
- Check66 days agoChange DetectedThe page has been updated to reflect an increase in study locations from 11 to 14, with specific new locations added in Arizona, Ohio, and Washington, including details about the institutions available at each site.SummaryDifference6%
- Check87 days agoChange DetectedThe webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to Expanded Access of Lifileucel in Melanoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access of Lifileucel in Melanoma: Clinical Trial page.